Stifel Maintains Hold on Health Catalyst, Lowers Price Target to $2

Benzinga Newsdesk www.benzinga.com Negative 89.9%

Neg 89.9% Neu 0% Pos 0%

Stifel analyst David Grossman maintains Health Catalyst (NASDAQ:HCAT) with a Hold and lowers the price target from $3.75 to $2.